JOHN J ORLOFF Insider Trading $ALXN ALEXION PHARMACEUTICALS, INC.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JOHN J ORLOFF.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JOHN J ORLOFF. JOHN J ORLOFF is EVP, Research & Development in ALEXION PHARMACEUTICALS INC ($ALXN) and Director in NOVELION THERAPEUTICS INC. ($QLTI) and See Remarks in NOVELION THERAPEUTICS INC. ($QLTI) and EVP and President, R&D in Baxalta Inc ($BXLT) and See Remarks in Baxalta Inc ($BXLT).
JOHN J ORLOFF in ALEXION PHARMACEUTICALS, INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of JOHN J ORLOFF: EVP, Research & Development
Holdings: 88,324 shares
Current Value: $11,280,741
Latest Transaction: Mar 02 2021
$ALXN Market Capitalization: $28.30B
$ALXN Previous Close: $127.72
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of JOHN J ORLOFF in ALEXION PHARMACEUTICALS, INC.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALXN, BXLT, NVLN
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 02 2021 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 24,473 | 0 | 88,324 | 63.9 K to 88.3 K (+38.33 %) |
| Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 93.53 | 40 | 3,741 | 63,851 | 63.8 K to 63.9 K (+0.06 %) |
| Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 157.96 | 3,261 | 515,108 | 63,811 | 67.1 K to 63.8 K (-4.86 %) |
| Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 157.96 | 18,134 | 2,864,447 | 67,072 | 85.2 K to 67.1 K (-21.28 %) |
| Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 40,677 | 0 | 85,206 | 44.5 K to 85.2 K (+91.35 %) |
| Jun 09 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 114.61 | 2,784 | 319,074 | 44,529 | 47.3 K to 44.5 K (-5.88 %) |
| Jun 11 2019 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 118.61 | 2,786 | 330,447 | 37,791 | 40.6 K to 37.8 K (-6.87 %) |
| Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 9,428 | 0 | 40,577 | 31.1 K to 40.6 K (+30.27 %) |
| Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 93.01 | 34 | 3,162 | 31,149 | 31.1 K to 31.1 K (+0.11 %) |
| Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 132.92 | 675 | 89,721 | 31,115 | 31.8 K to 31.1 K (-2.12 %) |
| Jun 12 2018 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Sell | S | 118.53 | 2,115 | 250,691 | 31,790 | 33.9 K to 31.8 K (-6.24 %) |
| Mar 02 2018 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 8,940 | 0 | 33,905 | 25 K to 33.9 K (+35.81 %) |
| Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 24,965 | 0 | 24,965 | 0 to 25 K |
Page: 1